Continuous Glucose Monitoring Following Hospital Discharge
Effect of Continuous Glucose Monitoring Following Hospital Discharge of Patients With Type 2 Diabetes
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Trevor Sobol
- Phone Number: (614) 688-6257
- Email: trevor.sobol@osumc.edu
Study Locations
-
-
Ohio
-
Columbus, Ohio, United States, 43203
- The Ohio State University Medical Center - Outpatient Care East
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Type 2 Diabetes
- Basal insulin use >10 units per day
- Hemoglobin A1c >8.0%
- Smartphone compatible with Clarity App
- Age ≥18 years
Exclusion Criteria:
- Type 1 DM
- Inability to consent
- Pregnancy
- Prisoners
- Discharge to skilled nursing facility
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Dexcom CGM
|
Wearable continuous glucose monitor
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in TIR 70-180 mg/dl
Time Frame: 12 weeks
|
Change in %time in range between 70-180 mg/dl from 2 weeks to 12 weeks.
|
12 weeks
|
|
% Wear Time >70%
Time Frame: 12 weeks
|
The number of participants with % wear time >70% will be reported.
|
12 weeks
|
|
DTSQc Score
Time Frame: 12 weeks
|
The DTSQc compares the experience of the current treatment with the experience of the treatment before initiation of the study.
Scores range from +3 ("much more satisfied now") to -3 ("much less satisfied now"), with 0 (midpoint) representing no change.
Higher scores on the DTSQ total score indicate higher treatment satisfaction, and lower scores indicate lower treatment satisfaction.
The total score ranges from -18 (maximum deterioration in satisfaction) to +18 (maximum improvement in satisfaction).A score of 0 indicates no change in satisfaction.
|
12 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Kathleen Dungan, MD, OSU Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2021H0426
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.